Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: It has been reported that pathological complete response is an important surrogate marker for disease-free survival and overall survival in patients with triple-negative breast cancer. This study investigates predictors of the response to neoadjuvant platinum-based or anthracycline-based treatment, and of the prognosis, in patients with triple-negative breast cancer.
Methods: A total of 121 patients with triple-negative breast cancer received neoadjuvant treatment with either platinum or anthracycline between 2008 and 2013. Pathological complete response was assessed relative to different treatments using logistic regression models with age, clinical tumor stage, grading, and Ki-67 as predictors and interaction terms, to obtain adjusted and subgroup-specific results. The impact of the pathological complete response rate on disease-free survival and overall survival was also analyzed.
Results: The pathological complete response rate was higher after platinum/taxane treatment compared with anthracycline/taxane (50.0% vs. 41.8%), but this was not significant in the adjusted analysis (OR 1.44; 95% CI, 0.68 to 3.09). A high histological grade (G3) was a predictor for higher pathological complete response in platinum-based therapy (OR 2.27; 95% CI, 1.00 to 5.30). The effect of neoadjuvant chemotherapy on pathological complete response was significantly different for G1-2 vs. G3 (P = 0.013), and additional subgroup-specific differences were noted. Pathological complete response was a predictor for improved disease-free survival and overall survival in both treatment groups, with and without platinum chemotherapy.
Conclusions: This retrospective study of patients with triple-negative breast cancer adds to the evidence that the treatment effect of platinum may be greatest particularly in G3 tumors. In addition, the effect of pathological complete response on the prognosis does not depend on the treatment used.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206705 | PMC |
| http://dx.doi.org/10.1186/s12885-018-4925-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intraoral vs. extraoral photobiomodulation therapy for oral mucositis in head and neck cancer patients: a multicenter, randomized, single-blind clinical trial.
Support Care Cancer
September 2025
Department of Oral Pathology, School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Purpose: To compare the efficacy of intraoral (IOPBM) and extraoral photobiomodulation (EOPBM) protocols for the prevention and treatment of oral mucositis (OM) in patients with oral or oropharyngeal squamous cell carcinoma (SCC) to submitted radiotherapy (RT).
Methods: This randomized, blinded, multicenter clinical trial enrolled 58 patients with oral or oropharyngeal SCC, who were allocated into two groups matched by treatment type, clinical stage, and RT modality. Group I (IOPBM) received intraoral photobiomodulation (PBM) with a continuous InGaAlP diode laser (660 nm, 100 mW, 0.
Orsay virus variants isolated from wild nematodes, France.
Microbiol Resour Announc
September 2025
Department of Molecular Microbiology, School of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.
Four new variants of Orsay virus were identified from wild isolates of nematodes collected from decaying plant matter in France. Near-complete genomes of the viruses were determined by metagenomic sequencing. The four genomes share 96.
View Article and Find Full Text PDFBarriers to professional social media use among medical laboratory scientists.
Lab Med
September 2025
Dermatopathology Section, Illinois Dermatology Institute, Park Ridge, IL, United States.
Introduction: Medical laboratory science professionals face obstacles related to social media use. We aimed to identify social media trends among the medical laboratory science workforce and barriers to professional use.
Methods: A 23-item qualitative survey was administered to American Society for Clinical Pathology members, with data collected and managed using Research Electronic Data Capture (REDCap) tools.
Impact of TP53, KRAS, and APC Mutations on Neoadjuvant Chemotherapy Outcomes in Locally Advanced Rectal Cancer.
Cancer Sci
September 2025
Department of Surgery, Asahikawa Medical University, Asahikawa, Japan.
Despite recent advances in neoadjuvant strategies for locally advanced rectal cancer (LARC), optimal chemotherapy regimens and the role of genetic biomarkers in guiding treatment remain unclear. Moreover, predictive markers are urgently needed for radiation-sparing strategies. Therefore, we aimed to assess the predictive and prognostic value of TP53, KRAS, and APC mutations in patients with LARC undergoing neoadjuvant chemotherapy (NACT) by retrospectively analyzing 43 patients with LARC who underwent NACT without radiation.
View Article and Find Full Text PDFWhen a Scrotal Mass Is More Than It Seems: A Case of Pediatric Paratesticular Rhabdomyosarcoma and Review of the Literature.
J Clin Ultrasound
September 2025
Division of Pediatric Surgery, Federico II University Hospital, Naples, Italy.
Paratesticular rhabdomyosarcoma (RMS) is a rare pediatric malignancy often misdiagnosed as benign conditions like epididymitis. We report a 4-year-old boy with paratesticular RMS and retroperitoneal metastasis, initially mistaken for epididymitis. The diagnostic delay resulted in disease progression, necessitating radical inguinal orchiectomy, hemiscrotectomy, and complete multimodal therapy.
View Article and Find Full Text PDF